• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Vibegron Intermediate CAS:1421271-01-3
Food Grade Fish Collagen
Vibegron Intermediate CAS:1295539-30-8
Vibegron Intermediate CAS:1426235-01-9
Vibegron Intermediate CAS:163625-46-5
Vibegron Intermediate

Laurus Labs’ net profit at Rs 48.8 crore in Q2 FY18

expressbpdNovember 14, 2017

Tag: Laurus Labs , net profit , Rs

Total revenue posted at Rs 538 crore

Hyderabad-based Laurus Labs’ net profit remained flat ₹48.8 crore in Q2 FY18, compared to ₹48.3 crore in Q2 FY17. The total revenue of company grew 4.3 per cent at Rs 538 crore (Rs 516 crore).

According to Satyanarayana Chava, CEO, Laurus Labs, the ARV (anti-retroviral) business witnessed a significant rise in revenues backed by strong customer offtake. He expects to maintain the momentum for the remaining half of the year.

Previous:Pfizer Q2 net dips to Rs 111 cr

Next:Merck Receives FDA Approval for GONAL-f Prefilled Pen

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Laurus Labs’ net profit at Rs 48.8 crore in Q2 FY18 | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

Tauroursodeoxycholic Acid

Tauroursodeoxycholic Acid
30 bracket covers 127×106×10

30 bracket covers 127×106×10
Boc-(2RS,3S)-AHPA

Boc-(2RS,3S)-AHPA
Proidra Horse Chestnut extract

Proidra Horse Chestnut extract
CAS 484-12-8 Osthole Powder Fruit Fructus Cnidii Snowparsley Plant Cnidium Monnieri Extract

CAS 484-12-8 Osthole Powder Fruit Fructus Cnidii Snowparsley Plant Cnidium Monnieri Extract
Capsule Filters 5

Capsule Filters 5
Budesonide EP Impurity L (Mixture of Diastereomers)

Budesonide EP Impurity L (Mixture of Diastereomers)
THIOMERSAL

THIOMERSAL
30*40cm 4 Layers Anti Static ESD Cleaning Cloth

30*40cm 4 Layers Anti Static ESD Cleaning Cloth

Sarsasapogenin--126-19-2

Sarsasapogenin--126-19-2

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service